Given that CD20 is a prominent therapeutic target in B cell lymphomas, CD20 membrane organization and mobility may not only influence its interactions with other membrane proteins, but also affect the accessibility of CD20-targeting antibody therapies. Here, MS4A1 is linked to B-cell non-Hodgkin lymphoma.